country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-24504

Copy Link Print Information

MBA-m1

Customer Review

Based on 1 Customer Validation

MBA-m1 is a reversible non-covalent allosteric inhibitor of mMLKL2, with a K_d value of 6 μM for mMLKL2. MBA-m1 delays Necroptosis. MBA-m1 has no effect on the activities of RIPK1 or RIPK3. MBA-m1 alleviates skin injury, epidermal thickening and immune cell infiltration in dermatitis models, and reduces aortic diameter enlargement and structural changes in abdominal aortic aneurysm models. MBA-m1 can be used in research related to dermatitis and abdominal aortic aneurysm.

For research use only. We do not sell to patients.

Purity: 98.20%
CAS No.: 305866-70-0
Formula: C₂₇H₂₁ClN₂O₂
Molecular Weight:440.92

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MBA-m1 Chemical Structure

CAS No.: 305866-70-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	CC₅₀	7.07 μM Compound: GNF-Pf-2622	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
SK-BR-3	IC₅₀	5 μM Compound: 33	Cytotoxicity against human SKBr3 cells after 72 hrs by MTT assay Cytotoxicity against human SKBr3 cells after 72 hrs by MTT assay	[PMID: 18500794]

In Vitro

MBA-m1 (10 μM) potently delays TSZ-induced necroptosis in wild-type mouse NIH-3T3 cells by inhibiting mMLKL activation and downstream cell death processes^[1].
MBA-m1 directly binds to purified recombinant mouse mMLKL2 protein, and this conclusion is confirmed by isothermal titration calorimetry^[1].
MBA-m1 (10 μM; 1 h pre-treatment) binds to mMLKL in wild-type mouse NIH-3T3 cells, which is confirmed by the increased thermal stability of mMLKL in cellular thermal shift assay^[1].
MBA-m1 (12.5-200 μM) binds to recombinant mouse MLKL (mMLKL2) with a K_d value of 6 μM^[2].
MBA-m1 (4-8 h post TSZ treatment; 1-10 μM) dose-dependently delays the necroptosis kinetics of NIH-3T3 cells^[2].
MBA-m1 (5-10 μM; 0-24 h post-TS treatment) does not affect RIPK1-mediated extrinsic apoptosis in wild-type or MLKL-knockout NIH-3T3 cells, which supports its specificity for MLKL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:

wild-type and MLKL knockout NIH-3T3 cells
Concentration:

5, 10 μM
Incubation Time:

0-24 h (post-TS treatment)
Result:

Had no discernible effect on the kinetics of RIPK1-mediated extrinsic apoptosis in either wild-type or MLKL knockout NIH-3T3 cells.

In Vivo

MBA-m1 (30 mg/kg; i.p.; every other day; 21 days) significantly ameliorates MLKL-driven dermatitis in Tnfr1^-/-;Hoip^E-KO mice, reducing skin inflammation severity, epidermal thickness, and immune cell infiltration^[1].
MBA-m1 (30 mg/kg; i.p.; every other day; 18 days) significantly attenuates abdominal aortic aneurysm progression in mice, reducing aortic dilation, structural damage, and immune cell infiltration^[1].
MBA-m1 significantly reduces dermatitis severity and disease progression in a necroptosis-driven mouse dermatitis model^[2].
MBA-m1 prevents aortic aneurysm development in a porcine pancreatic elastase-induced mouse model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6N mice (30-40 days old)^[1]
Dosage:

30 mg/kg
Administration:

i.p.; every other day; 21 days
Result:

Significantly ameliorated dermatitis with patches of healthy and moderately inflamed dorsal skin.
Reduced epidermal thickness compared to vehicle controls.
Decreased CD45-positive cell infiltration in both healthy and inflamed tissue compared to vehicle controls.
Lowered dermatitis severity scores at study endpoint compared to vehicle controls.

Chemical Information

CAS No. 305866-70-0
Appearance Solid
Molecular Weight 440.92
Formula C₂₇H₂₁ClN₂O₂
Color White to off-white
SMILES

ClC1=CC(NC2=CC(C)=NC3=C2C=C(OC)C=C3)=CC=C1OC4=CC5=C(C=CC=C5)C=C4
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ros U, et al. MLKL activity requires a splicing-regulated, druggable intramolecular interaction. Molecular cell. 2025 Apr 17;85(8):1589-1605.e12. [Content Brief]

[2]. Abdelwahab Y. Development of a New Class of Necroptosis Inhibitors That Bind Allosterically to Human and Mouse MLKL[D]. Universität zu Köln, 2025.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock